• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles 2,4,5-trisubstituted thiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles 2,4,5-trisubstituted thiazoles

Recent Advances in the Study of (4-Methyl-2-pyrid-4-yl-1,3-thiazol-5-yl)methylamine (CAS: 933742-59-7)

The compound (4-Methyl-2-pyrid-4-yl-1,3-thiazol-5-yl)methylamine (CAS: 933742-59-7) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This heterocyclic amine, featuring a pyridyl-thiazole scaffold, has been investigated for its role as a key intermediate in the synthesis of bioactive molecules targeting various diseases, including cancer, infectious diseases, and neurological disorders. Recent studies have highlighted its unique chemical properties and biological activities, making it a promising candidate for further drug development.

One of the most notable advancements in the study of this compound is its application in the development of kinase inhibitors. Kinases play a critical role in cell signaling pathways, and their dysregulation is often associated with cancer and other proliferative diseases. Researchers have synthesized derivatives of (4-Methyl-2-pyrid-4-yl-1,3-thiazol-5-yl)methylamine to explore their inhibitory effects on specific kinases, such as EGFR and BRAF. Preliminary results indicate that these derivatives exhibit potent inhibitory activity with high selectivity, suggesting their potential as next-generation targeted therapies.

In addition to its role in kinase inhibition, recent studies have also explored the compound's antimicrobial properties. The thiazole moiety, a common feature in many antimicrobial agents, has been shown to enhance the compound's ability to disrupt bacterial cell membranes and inhibit essential enzymes. For instance, a 2023 study demonstrated that derivatives of (4-Methyl-2-pyrid-4-yl-1,3-thiazol-5-yl)methylamine exhibited significant activity against drug-resistant strains of Staphylococcus aureus and Escherichia coli, highlighting its potential as a scaffold for novel antibiotics.

The synthesis and optimization of (4-Methyl-2-pyrid-4-yl-1,3-thiazol-5-yl)methylamine have also been a focus of recent research. Advances in synthetic methodologies, such as microwave-assisted reactions and flow chemistry, have enabled more efficient and scalable production of this compound. These innovations not only improve yield and purity but also reduce the environmental impact of the synthesis process, aligning with the growing emphasis on green chemistry in pharmaceutical development.

Furthermore, computational studies have provided valuable insights into the compound's mechanism of action and structure-activity relationships (SAR). Molecular docking and dynamics simulations have revealed key interactions between the compound and its biological targets, guiding the design of more potent and selective derivatives. These in silico approaches, combined with experimental validation, have accelerated the discovery of novel analogs with enhanced therapeutic profiles.

Despite these promising developments, challenges remain in the clinical translation of (4-Methyl-2-pyrid-4-yl-1,3-thiazol-5-yl)methylamine-based therapeutics. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further preclinical and clinical studies. However, the compound's versatility and demonstrated bioactivity make it a compelling subject for ongoing research.

In conclusion, (4-Methyl-2-pyrid-4-yl-1,3-thiazol-5-yl)methylamine (CAS: 933742-59-7) represents a promising scaffold in medicinal chemistry, with applications ranging from kinase inhibition to antimicrobial therapy. Recent advancements in synthesis, computational modeling, and biological evaluation have underscored its potential, paving the way for future drug discovery efforts. Continued research in this area is expected to yield novel therapeutics that address unmet medical needs across a spectrum of diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)